Prevalence and nature of potential drug–drug interactions among kidney transplant patients in a German intensive care unit
暂无分享,去创建一个
Christian Trautwein | C. Trautwein | A. Koch | A. Eisert | Julia Amkreutz | Alexander Koch | Lukas Buendgens | Anja Muehlfeld | Albrecht Eisert | L. Buendgens | A. Muehlfeld | J. Amkreutz | Julia Amkreutz
[1] Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis , 2012, European Journal of Clinical Pharmacology.
[2] A. Forster,et al. Incidence and Contributors to Potential Drug‐Drug Interactions in Hospitalized Patients , 2011, Journal of clinical pharmacology.
[3] P. Beaune,et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] Lisa E. Hines,et al. Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions , 2011, J. Am. Medical Informatics Assoc..
[5] Amy J Grizzle,et al. Concordance of severity ratings provided in four drug interaction compendia. , 2004, Journal of the American Pharmacists Association : JAPhA.
[6] Manuel Battegay,et al. Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] SUPPORTING TABLES,et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] N. Laird,et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .
[9] S D Small,et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. , 1995, JAMA.
[10] Shiew-Mei Huang,et al. Recommendations for selecting drug-drug interactions for clinical decision support. , 2016, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[11] S. Secoli,et al. Prevalence of potential drug–drug interactions in bone marrow transplant patients , 2011, International Journal of Clinical Pharmacy.
[12] C. Trautwein,et al. Clinical decision support systems differ in their ability to identify clinically relevant drug interactions of immunosuppressants in kidney transplant patients , 2017, Journal of clinical pharmacy and therapeutics.
[13] W. Nahas,et al. Diminished Mycophenolic Acid Exposure Caused by Omeprazole May Be Clinically Relevant in the First Week Posttransplantation , 2012, Therapeutic drug monitoring.
[14] J. Ragnaud,et al. Drug–drug interactions with systemic antifungals in clinical practice , 2007, Pharmacoepidemiology and drug safety.
[15] N. Siddiqi,et al. Clinically Significant Drug−Drug Interaction Between Tacrolimus and Phenobarbital , 2010, Journal of pharmacy practice.
[16] Adriano Max Moreira Reis,et al. Evaluation of three brands of drug interaction software for use in intensive care units , 2010, Pharmacy World & Science.
[17] G. Kullak-Ublick,et al. Comparative Performance of Two Drug Interaction Screening Programmes Analysing a Cross-Sectional Prescription Dataset of 84,625 Psychiatric Inpatients , 2013, Drug Safety.
[18] John R Horn,et al. Proposal for a New Tool to Evaluate Drug Interaction Cases , 2007, The Annals of pharmacotherapy.
[19] R. Mathijssen,et al. Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs , 2013, British Journal of Cancer.
[20] K. Johnell,et al. The Relationship between Number of Drugs and Potential Drug-Drug Interactions in the Elderly , 2007, Drug safety.
[21] S. Krähenbühl,et al. Evaluation of frequently used drug interaction screening programs , 2008, Pharmacy World & Science.
[22] Alissa L. Russ,et al. Recommendations to improve the usability of drug-drug interaction clinical decision support alerts , 2015, J. Am. Medical Informatics Assoc..
[23] Michael A. Wittie,et al. Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support , 2015, Drug Safety.
[24] G. V. Ramos,et al. Comparison of two databases to detect potential drug–drug interactions between prescriptions of HIV/AIDS patients in critical care , 2015, Journal of clinical pharmacy and therapeutics.
[25] Olivier Bodenreider,et al. Comparison of three commercial knowledge bases for detection of drug-drug interactions in clinical decision support , 2017, J. Am. Medical Informatics Assoc..
[26] Bruce Kaplan,et al. Evaluation of Drug Interaction Software to Identify Alerts for Transplant Medications , 2005, The Annals of pharmacotherapy.
[27] T Welte,et al. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. , 2000, International journal of clinical pharmacology and therapeutics.
[28] T. Jones. The Use of Other Drugs to Allow a Lower Dosage of Cyclosporin to Be Used , 1997, Clinical pharmacokinetics.
[29] J. M. Cruciol-Souza,et al. Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[30] S. Mezzano,et al. No gender-associated differences of cyclosporine pharmacokinetics in stable renal transplant patients treated with diltiazem. , 2005, Transplantation proceedings.
[31] S. Krähenbühl,et al. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT , 2010, Bone Marrow Transplantation.
[32] Piera Polidori,et al. Incidence of potential drug interactions in a transplant centre setting and relevance of electronic alerts for clinical practice support. , 2013, Informatics in primary care.
[33] A. Vitry,et al. Comparative assessment of four drug interaction compendia. , 2007, British journal of clinical pharmacology.
[34] M. Ghoneim,et al. Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome. , 2003, Journal of nephrology.
[35] M. Weir,et al. Drug interactions in transplant patients: what everyone should know , 2009, Current opinion in nephrology and hypertension.
[36] David W Bates,et al. Frequency of potential azole drug–drug interactions and consequences of potential fluconazole drug interactions , 2005, Pharmacoepidemiology and drug safety.
[37] Edward P. Armstrong,et al. Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. , 2004, Journal of the American Pharmacists Association : JAPhA.
[38] J. Crowley,et al. ACUTE RENAL TOXICITY WITH COMBINED USE OF AMPHOTERICIN B AND CYCLOSPORINE AFTER MARROW TRANSPLANTATION , 1983, Transplantation.